Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aceclidine + Brimonidine (LNZ101) and Aceclidine (LNZ100) in Presbyopia
NCT05431543Phase 2Completed
- Sponsor
- LENZ Therapeutics
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aceclidine and brimonidine tartrate + sodium hyaluronate in presbyopia (3 arms), sponsored by LENZ Therapeutics. Primary endpoint: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision at 1 hour. Started Aug 2022; status: completed.
02
Drugs
aceclidinebrimonidine tartrate + sodium hyaluronate
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT05431543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431543.